About Us

Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
My Watchlist
Indicators
Local Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Dr. Reddy's Laboratories Ltd Common Stock (NY:RDY)

13.63 +0.14 (+1.07%)
Streaming Delayed Price Updated: 10:10 AM EDT, May 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Dr. Reddy's Laboratories Ltd Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Teva Pharmaceuticals Stock: Unlock Value in This Generic Drug Gem
Drug prices continue to rise, driving up healthcare costs. Pharmaceutical companies usually hike drug prices at the beginning of each year. In January 2024 
Via MarketBeat
News headline image
Should Quality-Oriented Investors Explore DR. REDDY'S LABORATORIES-ADR (NYSE:RDY)? ↗
DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) can be considered a quality stock. Here's why. 
Via Chartmill
News headline image
Dr. Reddy's Labs Stock Sees Improved Technical Strength ↗
On Friday, Dr. Reddy's Labs ADR stock earned an upgrade to its Relative Strength (RS) Rating, from 66 to 76. 
Via Investor's Business Daily
News headline image
Haleon To Offload Non-Core Nicotine Therapy Business To Dr. Reddy's For Over $600M ↗
Haleon has agreed to sell its nicotine replacement therapy business outside the U.S. to Dr. Reddy's Laboratories SA for £500 million ($632 million). This strategic move allows Haleon to focus on growth... 
Via Benzinga
News headline image
Aurigene Pharmaceutical Services Limited, a Global CRDMO, Announces the Opening of Its Biologics Facility Offering Process Development and Clinical Scale Manufacturing Capabilities
From Aurigene Pharmaceutical Services Ltd.
Via Business Wire
News headline image
Dr Reddy's Laboratories: Q3 Earnings Insights ↗
 
Via Benzinga
News headline image
Dr. Reddy’s to Acquire Nicotinell and Related Portfolio in Significant Step Towards Building Global Consumer Healthcare Business
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
India Stocks Rally On Modi Election Wave. This Indian Bank Stock Hits High. ↗
Exit polls forecast a landslide win and third consecutive term for Prime Minister Narendra Modi in India's general elections. 
Via Investor's Business Daily
News headline image
Dr. Reddy's Laboratories Announces the Appointment of Milan Kalawadia to CEO North America
From Dr. Reddy's Laboratories Ltd.
Via Business Wire
News headline image
Is NYSE:RDY suited for quality investing? ↗
Exploring DR. REDDY'S LABORATORIES-ADR (NYSE:RDY)'s quality characteristics. 
Via Chartmill
News headline image
Alvotech and Dr. Reddy’s Enter Into Collaboration for Commercialization of AVT03 (denosumab), a Biosimilar Candidate to Prolia® & Xgeva® in the U.S., Europe and UK
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UK
From Alvotech
Via GlobeNewswire
News headline image
Should you consider NYSE:RDY for quality investing? ↗
DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) may be suited for quality investing, we'll explore why in this article. 
Via Chartmill
News headline image
Chart Of The Day: What's Cooking At Dr. Reddy's Lab ↗
100% technical buy signals 12 new highs and up 10.76% in the last month 38.40+ Weighted Alpha 
Via Talk Markets
News headline image
RDY Stock Earnings: Dr Reddy’s Laboratories Beats EPS, Misses Revenue for Q4 2024 ↗
RDY stock results show that Dr Reddy's Laboratories beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2024. 
Via InvestorPlace
News headline image
Dr. Reddy’s Q4 & Full Year FY24 Financial Results
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
Dr. Reddy's Laboratories Announces the Launch of Doxycycline Capsules, 40 mg* in the U.S.
From Dr. Reddy's Laboratories Ltd.
Via Business Wire
News headline image
Dr. Reddy's Laboratories launches Versavo® (bevacizumab) in the UK
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
Global Access to Weight-Loss Treatments: Indian Pharma Giants Eye Affordable Wegovy Alternatives Amid Rising Demand ↗
Indian pharmaceutical giants, including Sun Pharma and Cipla, seize the opportunity to develop affordable versions of Novo Nordisk's Wegovy weight-loss treatment. With patents set to expire by... 
Via Benzinga
Topics Intellectual Property
News headline image
Dr. Reddy’s Q3 & 9M FY24 Financial Results
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
Dr. Reddy's Announces the Acquisition of MenoLabs®, a Leading Women’s Health and Dietary Supplements Portfolio of Brands
From Dr. Reddy's Laboratories Ltd.
Via Business Wire
News headline image
Dr. Reddy’s becomes first Indian pharma company to debut on the Dow Jones Sustainability World Index
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
Coya Therapeutics, Inc. and Dr. Reddy’s Laboratories Enter into an Exclusive Collaboration for Development and Commercialization of COYA 302, an Investigational Combination Therapy for Treatment of Amyotrophic Lateral Sclerosis (ALS)
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
2 overlooked stocks that crushed earnings but traded lower
As the third quarter 2023 earnings season ends, it's worth looking back to see which stocks may have been overlooked or mispriced on their results 
Via MarketBeat
News headline image
Dr. Reddy’s Q2 FY24 Financial Results
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
Why Quality Investors Should Delve into DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) for Investment Opportunities. ↗
Reasonable Growth, Debt Levels, and a High ROIC Make DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) Appealing to Quality Investors. 
Via Chartmill
News headline image
Top 5 Health Care Stocks That May Fall Off A Cliff ↗
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
News headline image
Dr. Reddy's Laboratories Announces its Launch of Saxagliptin and Metformin Hydrochloride Extended-Release Tablets in the U.S.
From Dr. Reddy's Laboratories Ltd.
Via Business Wire
News headline image
Dr. Reddy’s Q1 FY24 Financial Results
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
Dr. Reddy’s Proposed Rituximab Biosimilar Application Accepted for Review by USFDA, EMA and MHRA
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.